Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice.
Parkinson's disease (PD) is a progressive neurodegenerative disorder whose etiology is not understood. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model is widely used for studying PD. The present study was undertaken to investigate the effect of hydroxysafflor yellow A (HSYA) on MPTP-induced neurotoxicity in mice. Pretreatment with HSYA at a dose of 2, 8 mg/kg for a week was followed by intraperitoneal injection with MPTP (30 mg/kg) for five consecutive days. Next, the subsequent behavior, biochemical index and immunohistochemical manifestations in mice were determined. Behavioral testing showed that MPTP-treated mice exhibited motor deficits but HSYA at dose of 8 mg/kg prevented the appearance of motor abnormalities. Treatment with HSYA at dose of 8 mg/kg attenuated the reduction of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in striatum. It also showed that the activity of SOD, catalase activity and GSH levels were significantly higher, while the levels of malondialdehyde (MDA) and hydroxyl radicals was lower, in the HSYA-treated mice compared to the MPTP-treated mice. The MPTP-treated mice exhibited the loss of tyrosine hydroxylase-containing dopaminergic neurons in substantia nigra. However, HSYA-treated mice showed a protective effect. Our results indicated that HSYA possesses neuroprotective effects and is a promising anti-Parkinson's disease drug which is worthy of further study.
Han
B
B
Department of Physiology, School of Basic Medical Sciences, Jilin University, No. 2 Xinmin Street, Changchun 130021, China.
Zhao
H
H
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D002374:Catalase / Q000378:metabolism; D002599:Chalcone / Q000031:analogs & derivatives* / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D007150:Immunohistochemistry; D020267:MPTP Poisoning / Q000517:prevention & control*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D011809:Quinones / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000378:metabolism
D011809:Quinones; D015102:3,4-Dihydroxyphenylacetic Acid; C085278:hydroxysafflor yellow A; D008315:Malondialdehyde; D002599:Chalcone; D002374:Catalase; D013482:Superoxide Dismutase; D005978:Glutathione; D004298:Dopamine; D006719:Homovanillic Acid
Invest Ophthalmol Vis Sci. 1993 Jan;34(1):72-80
8425843
Brain Res. 2000 Jan 3;852(1):221-4
10661517
Eur J Pharm Sci. 2001 Jan;12(3):231-8
11113642
Neurosci Lett. 2005 Sep 23;386(1):58-62
16002219
Chem Res Toxicol. 2008 Jan;21(1):172-88
18052107
Anal Biochem. 1979 Jun;95(2):351-8
36810
Brain Res. 1987 Feb 3;402(2):269-74
3493826
Brain Res. 2002 Aug 30;947(2):271-83
12176170
Exp Neurol. 2004 Feb;185(2):281-9
14736509
Brain Res. 1990 Oct 1;528(2):181-8
2271921
Neurochem Res. 2002 Jun;27(6):457-64
12199149
Methods Enzymol. 1984;105:121-6
6727660
J Biol Chem. 1951 Nov;193(1):265-75
14907713
Mol Neurobiol. 1998 Jun;16(3):285-309
9626667
J Neurochem. 1993 Oct;61(4):1191-206
8376979
J Biol Chem. 1969 Nov 25;244(22):6049-55
5389100
Behav Genet. 2000 May;30(3):171-82
11105391
FASEB J. 1998 Jul;12(10):905-12
9657530
Adv Neurol. 1987;45:19-34
2881444
Pharmacology. 2008;82(2):121-6
18583922
Science. 1983 Feb 25;219(4587):979-80
6823561
Anal Biochem. 1966 Mar;14(3):434-40
5944947
Mov Disord. 1998;13 Suppl 1:35-8
9613716
Neurochem Res. 2008 Jun;33(6):980-4
17768676
J Neural Transm (Vienna). 2001;108(11):1263-82
11768626